Mode
Text Size
Log in / Sign up
N/A N=56 Randomized Single-blind Other

Opportunities and Limits to Deprescribing in Nursing Homes:Quality Circle Deprescribing Module

Polypharmacy · Inappropriate Prescribing

Enrolled (actual)
56
Serious AEs
Results posted
Apr 2021
Primary outcome: Primary: Percentage of Potentially Inappropriate Galenic Units — 24; 23 percent — p=<0.05

Study Design & Population

Study type
Interventional
Phase
N/A
Interventions
Quality Circle Deprescribing Module (Other)
Age
Pediatric, Adult, Older Adult
Sex
All
Sponsor
Anne Niquille
Primary completion
Jul 2020

Outcome Measures

OutcomeResultp-value
PRIMARY
Percentage of Potentially Inappropriate Galenic Units
24; 23 <0.05 sig
PRIMARY
Number of Potentially Inappropriate Defined Daily Doses (DDDs) Per Average Resident and Per Day
2.1; 2.3 <0.05 sig
SECONDARY
Number of Potentially Inappropriate DDD to Avoid
0.3; 0.3 <0.05 sig
SECONDARY
Number of Potentially Inappropriate DDD to Reevaluate
1.8; 2.0 <0.05 sig
SECONDARY
Number of Hospital Days
3.1; 2.5 <0.05 sig
SECONDARY
Mortality Rate
31; 38 <0.05 sig
SECONDARY
Number of Falls Per Average Resident and Per Year
3.0; 2.6 <0.05 sig
SECONDARY
Percentage of Residents With at Least One Day of Physical Restraints Use
33; 37 <0.05 sig

Summary

Older people residing in nursing homes (NH) are frequently polymedicated and often prescribed potentially inappropriate medications. Deprescribing has been proposed as a way to reduce the number of drugs they receive and their exposure to harmful treatments. The objectives of this study are 1) To evaluate the effect of a deprescribing-specific interdisciplinary quality circle module on the use of potentially inappropriate medication in nursing-home residents. 2) To determine the effective strategies to reach and implement deprescribing consensus resulting of said quality circle module.

Eligibility Criteria

Inclusion Criteria

Nursing homes taking part in the study must have

  • a geriatric of psycho-geriatric mission;
  • been part of their cantonal pharmaceutical assistance program for at least a year.

Exclusion Criteria

  • None
View full record on ClinicalTrials.gov →

Data sourced from ClinicalTrials.gov (NCT03688542). Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication.

Back to search